Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of new strength formulations of cefotaxime (powder for injection: 500 mg; 1 g; 2 g (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc. - the addition of new formulations of amoxicillin (dispersible, scored tablet, 250 mg and 500 mg) to the EMLc. - the deletion of oral formulations of chloramphenicol (capsule 250 mg and oral liquid 150 mg/5 mL (as palmitate)) from the EML and EMLc.